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T
here are a handful of biological 
questions that affect all of 
us directly in everyday life. 
How are emotions formed, what is 
the basis for consciousness, and why 
do we look the way we do? One that 
strikes particularly close to home is 
the question of how we age. The sheer 
complexity of this problem has had 
many scientists throw up their hands in 
frustration and most of the postulated 
theories have been vague and generally 
have involved ill-deﬁ  ned wear-and-
tear mechanisms. But the pursuit of 
the biological basis of aging has been 
revitalized within the last decade by 
studies in yeast, worms, ﬂ  ies, and 
mice that have ﬁ  rmly established that 
there indeed exist speciﬁ  c molecular 
mechanisms that contribute to the 
aging process [1]. These efforts point 
to several distinct, likely interrelated, 
mechanisms, ranging from improper 
protein metabolism, to alterations of 
speciﬁ  c signaling pathways, progressive 
damage due to generation of oxidative 
free radicals, and increased genome 
instability.
Although much has been learned 
about the aging process from simple 
model organisms, one intuitively 
suspects that things might be somewhat 
different when it comes to human 
aging. So how does one best study the 
molecular basis of human aging? The 
answer might be premature aging 
diseases, or progeroid syndromes. The 
advantage of these often rare diseases 
is that they are mostly monogenic and 
thus experimentally tractable. On the 
other hand, one should keep in mind 
that such disorders usually only mimic 
some of the features of normal aging 
and it can be difﬁ  cult to distinguish 
true aging symptoms from unrelated 
developmental defects. Regardless, it 
appears that progeroid syndromes may 
be legitimately used as model systems to 
investigate the physiological processes 
contributing to aging. In fact, the study 
of some of these diseases has recently 
brought tantalizing clues as to how we 
age. One of the most intriguing ones 
is a possible involvement of structural 
components of the cell nucleus [2].
Aging and the Cell Nucleus
The cell nucleus in higher organisms 
is now recognized as a complex, 
highly organized repository of an 
individual’s genetic information. 
The typical nucleus contains distinct 
functional neighborhoods made up by 
nonrandomly positioned chromosomes 
and proteinaceous subcompartments 
in which speciﬁ  c processes, including 
gene expression, occur [3]. Which 
molecular mechanisms establish and 
maintain the structural integrity of 
the nucleus is largely unknown and 
represents one of the most exciting 
ﬁ  elds in modern cell biology. Having 
said that, one of the major structural 
elements of the nucleus, the nuclear 
lamina, has been known and studied 
for decades [2]. The lamina is made 
up of A-, and B-type lamins, which are 
intermediate ﬁ  lament proteins that 
form an interwoven network situated 
at the very periphery of the nucleus 
underlying the nuclear membrane. 
This structure has long been thought 
to act as a shield to protect the 
genome from mechanical stress. More 
recently, this architectural feature of 
the nucleus has also been recognized 
as potentially playing a regulatory role 
in gene expression because lamins 
interact with chromatin and might 
serve to anchor and organize genome 
regions in space [2].
The ﬁ  rst hint to a surprising 
connection between nuclear 
architecture and aging came from 
yeast, when Leonard Guarente and 
colleagues found that a protein, 
Sir4, whose mutation results in 
extension of life span, localizes 
to the nucleolus, one of the most 
prominent subcompartments of the 
cell nucleus [4]. The link between 
aging and nuclear organization 
was further strengthened by the 
observation that the localization of 
the protein and the morphology of 
the nucleolus itself changed as yeast 
cells aged. However puzzling and 
provocative these observations were, it 
was unclear whether these structural 
reorganizations were a cause or 
consequence of aging, and it seemed 
a stretch to imagine that the same 
mechanisms might apply to human 
cells.
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Figure 1. Hutchinson-Gilford Progeria 
Syndrome
HGPS is a childhood disorder caused by 
mutations in one of the major architectural 
proteins of the cell nucleus. In HGPS patients 
the cell nucleus has dramatically aberrant 
morphology (bottom, right) rather than the 
uniform shape typically found in healthy 
individuals (top, right).PLoS Biology  |  www.plosbiology.org 1856
Hutchinson-Gilford Progeria 
Syndrome
The deﬁ  nitive proof for a causal 
connection between nuclear 
architecture and human aging came 
with a stunning discovery in the 
summer of 2003, when the groups 
of Francis Collins and Nicolas Levy 
identiﬁ  ed mutations in the lamin A 
gene (LMNA) as the genetic cause of 
the segmental premature aging disease 
Hutchinson-Gilford progeria syndrome 
(HGPS) [5,6] (Box 1). Children with 
HGPS usually experience normal 
fetal and early postnatal development 
but die of severe atherosclerosis at 
an average age of 13 years [7]. The 
initial physical signs of HGPS include 
severe failure to thrive, heralding 
severe lipoatrophy, bony abnormalities, 
a small, beaked nose and receding 
mandible, complete hair loss, and 
speckled hypopigmentation with some 
areas of tight, hard skin. As the disease 
progresses, vascular plaques become 
pervasive, leading to strokes and heart 
attacks. In short, these children give 
the distinct physical impression of 
being many decades older that they 
really are. However, HGPS children are 
neurologically unaffected, so that their 
emotional and developmental stages 
are age-appropriate. A six-year-old with 
HGPS may look physically like an old 
person, but is ready to enter ﬁ  rst grade 
along with the rest of his or her peers 
(Figure 1). In a sense, for families and 
friends, having a child whose mind and 
personality progress normally is a great 
fortune. In another sense, watching a 
child whose mind is so full of promise 
and joy experience angina, strokes, and 
heart attacks that are usually reserved 
for the elderly is devastating.
The involvement of lamin A in 
this disease was initially puzzling. It 
is not apparent how a protein whose 
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Box 1. The Cell Biology of HGPS 
In more than 80% of cases the gene 
defect responsible for HGPS is a single 
spontaneous mutation in codon 608 
of the LMNA gene, which encodes 
both lamin A and lamin C [6]. This base 
change produces a silent amino acid 
mutation and would therefore have no 
consequences for the lamin A protein. 
Unfortunately, the mutation activates a 
cryptic splice site in LMNA, resulting in 
aberrant removal of a part of the LMNA
RNA during the RNA splicing reaction 
and generation of a protein lacking 50 
amino acids towards its C-terminal end. 
This mutant protein is referred to as 
progerin. The progerin protein appears 
to act in a dominant negative fashion, 
and although its modus operandi 
is unclear at the moment, its action 
seems to be related to its extensive 
post-translational modiﬁ  cations. 
Normal lamin A is produced as a pre-
lamin A protein that undergoes a 
complex set of modiﬁ  cations starting 
with carboxymethylation, followed by 
cleavage of the terminal three amino 
acids, farnesylation at the C-terminus, and 
subsequent proteolysis of its terminal 
15 amino acids, leading to the removal 
of the farnesyl group. Although it can 
be farnesylated, pre-progerin lacks the 
endoprotease recognition site necessary 
for executing the ﬁ  nal cleavage step 
and thus accumulates in a farnesylated 
form [19]. Since the farnesyl group is 
important for the protein’s localization 
to the nuclear periphery, progerin 
accumulates in the lamina and this is 
presumably where it exerts its negative 
functional effects. Consistent with that notion, loss of the protease responsible for the cleavage event leads to premature aging in mice 
and humans [20,21]. Given the critical importance of the lamins in nuclear architecture, it is not surprising that the cells of HGPS patient 
are characterized by dramatic aberrations in nuclear architecture, particularly changes in the formation of their shape, loss of internal 
heterochromatin, and changes in the distribution of numerous nuclear proteins [14,22].
DOI: 10.1371/journal.pbio.0030395.g001
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function is to maintain proper nuclear 
architecture may cause premature 
aging. Two hypotheses rapidly emerged 
based on what cell biologists had 
learned about this intensely studied 
protein in the last two decades. It could 
be that the mutant lamin A protein 
weakens the nuclear lamina and in 
that way reduces the resistance of the 
cells of HGPS patients to the types of 
mechanical stress encountered in the 
body, heralding cellular dysfunction 
and death. This explanation makes 
much sense since many of the 
primarily affected tissues, such as skin 
and vasculature, are under intense 
mechanical stress. On the other hand, 
recent work showing that lamins 
directly and indirectly interact with 
chromatin point to the possibility that 
changes in the lamina might lead to 
misregulation of sets of genes in HGPS 
patients. Although plausible, it is not 
obvious how the gene misregulation 
model can account for the aging effect 
seen in patients, particularly since it has 
so far proven difﬁ  cult to identify sets of 
genes that are commonly misregulated 
in these patients. Even the mechanical 
stress model is not completely satisfying 
since it is based on one of those ill-
deﬁ  ned wear-and-tear scenarios so 
often invoked in the aging process. The 
distinct possibility that aspects of both 
models might apply is suggested by the 
fact that several genes that respond 
to mechanical signal transduction via 
the cytoskeleton are affected in cells 
lacking lamin A [8].
A possible breakthrough in 
understanding how a structural protein 
of the cell nucleus may be a key player 
in aging came just a few months ago. 
Zhang and colleagues discovered that 
cells in HGPS patients have increased 
genomic instability and DNA damage 
and that the DNA repair machinery 
does not function as effectively as it 
does in healthy individuals [9]. In 
particular, it appears that in the cells 
of individuals with HGPS, the repair 
machinery is not as efﬁ  ciently recruited 
to sites of damage, and, consequently, 
DNA breaks are less efﬁ  ciently 
repaired. Although unproven at this 
point, one can imagine that defects 
in the lamina structure could prevent 
the efﬁ  cient capture of repair factors 
[9,10]. Admittedly, increased genome 
instability must also be considered 
a wear-and-tear mechanism, but it 
deserves more credence than some of 
the other mechanisms because genome 
instability is a feature shared amongst 
virtually all premature aging disorders.
Genomic Instability and Aging
The clearest link between genomic 
instability and accelerated aging comes 
from a different progeroid disease, 
Werner syndrome (WS). This is an 
autosomal recessive disorder resulting 
from loss of function of a DNA 
helicase, the WRN RecQ helicase [11]. 
Compared to HGPS, this condition has 
a later onset, with patients developing 
normally until puberty and showing 
aging symptoms in early adulthood. 
Death generally occurs in the ﬁ  fth 
decade of life, mainly because of 
cancer and cardiovascular disease. 
Extensive research over the past decade 
has shed light on the molecular and 
cellular defects underlying the disease 
phenotype, making WS a perfect 
example of how important cell biology 
can be in unraveling mechanisms of 
premature aging. The WRN protein 
is involved in DNA replication and 
recombination and its main function 
is to reinitiate stalled replication forks. 
In the cells of WS patients, the absence 
of the WRN protein results in defective 
replication, inefﬁ  cient DNA repair, and 
chromosome rearrangements. Thus, 
altered DNA metabolism in WS cells 
directly causes defective maintenance 
of genome integrity, and this, in turn, 
results in cancer predisposition in 
patients [11].
The complex nature of the interplay 
between nuclear architecture, DNA 
metabolism, and aging becomes clear 
when considering a subset of patients 
who were diagnosed with WS based on 
their clinical symptoms, but, puzzlingly, 
do not carry a mutation in the WRN 
gene—instead, they have mutations 
in LMNA [12]. Clearly, the fact that 
WS symptoms can be recapitulated by 
mutations in a gene that gives rise to 
another premature aging disease is 
hardly coincidental. This remarkable 
conﬂ  uence of observations reinforces 
the idea that HGPS and WS might 
share a similar underlying molecular 
mechanism, possibly genomic instability.
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Figure 2. The Disease–Discovery–Therapy Cycle
Diseases are clinically deﬁ  ned by their symptoms. The genetic basis of disease is revealed by 
gene discovery. The cellular and molecular basis of a disease is characterized by cell biological 
approaches. These in turn provide the foundation to develop targeted therapies to alleviate 
symptoms and to fully understand the pathophysiology of the organismal disease symptoms.PLoS Biology  |  www.plosbiology.org 1858
Accelerated aging, however, 
probably does not involve only genomic 
instability. WS has also been critical in 
revealing a potential role of cellular 
senescence in the aging process 
[13]. Cells entering senescence, i.e., 
permanent arrest of cell division, 
undergo phenotypic changes and 
display several functional abnormalities 
compared to their proliferating 
counterparts. A second hallmark of 
cells in WS patients is short replicative 
life span in culture, due to telomere 
dysfunction. Although the molecular 
details of how the WRN protein affects 
telomere metabolism are not fully 
understood, the picture emerging 
is that accumulation of senescent, 
dysfunctional cells in WS patients might 
compromise the effectiveness of tissues 
and organs, leading to accelerated 
aging. Extending this model, cellular 
senescence has been postulated to also 
play a key role in physiological aging.
These observations on WS and the 
occurrence of genomic instability in 
premature aging diseases crystallize 
a tantalizing antagonism between 
aging and cancer [13]. That these 
two are linked is clear from the fact 
that age is the single largest risk 
factor for the development of cancer. 
In addition, genomic instability as 
seen during aging is a hallmark of 
cancer cells. Paradoxically, what we 
have learned from WS suggests that 
increased senescence appears to lead 
to premature aging, but on the other 
hand, cellular senescence is now also 
recognized as a defense mechanism 
to effectively stop potentially harmful, 
cancer-forming cells from proliferating. 
Clearly, organisms must ﬁ  nd a ﬁ  ne 
balance between these opposing 
effects. How this equilibrium is 
achieved during the physiological 
aging process is one of the fascinating 
mysteries of aging.
Finding the Fountain of Youth
One of the lures of aging research 
is of course to ﬁ  nd a fountain of 
youth—an elixir that prolongs life. 
Although several commercial entities 
are unleashing their resources 
at this tempting goal, given the 
inconclusive nature of most molecular 
aging pathways currently under 
consideration, these efforts seem 
unlikely to come to fruition in the 
near future. However, therapeutic 
intervention may be realistic for 
premature aging disorders as their 
molecular basis is becoming well 
deﬁ  ned. The feasibility of anti-aging 
intervention is made clear in the case of 
HGPS. Since the discovery of its genetic 
cause less than two years ago, at least 
two fascinating, yet realistic, strategies 
of molecular treatment have been 
opened. The ﬁ  rst is based on correcting 
the primary defect at the level of 
pre-mRNA. This strategy involves 
correcting the aberrant splicing event 
caused by the HGPS mutation (Box 
1). Proof of principle that this is 
possible has recently been provided by 
introduction of small oligonucleotides 
speciﬁ  cally targeted to the HGPS 
splice site, preventing its use and 
restoring normal splicing and cellular 
behavior [14]. If these results from cell 
culture experiments can be extended 
to organisms, they might provide a 
promising avenue of intervention. A 
second potential therapeutic approach 
for HGPS is founded in the complex 
post-translational processing of the 
lamin A protein by farnesylation (Box 
1). Inhibitors of the farnesylation 
reaction, so called farnesyl transferase 
inhibitors, have recently been 
developed as potential cancer 
therapeutics and might also be effective 
in HGPS. The hope would be that these 
inhibitors will decrease the amount 
of harmful farnesylated pre-progerin 
in the cell and thus alleviate cellular 
HGPS symptoms. Fortunately, ongoing 
clinical trials on farnesyl transferase 
inhibitors show little toxicity, and early 
studies in cell culture have already 
shown a reversal of some of the cellular 
defects associated with HGPS [15–18].
The story of HGPS is an impressive 
example of the interplay of basic and 
clinical science. It is also a showcase for 
how modern biology deals with disease 
(Figure 2). Within less than two years, 
we have gone from only knowing the 
symptoms of the disease to identifying 
the disease-causing gene and learning 
much about how the mutant protein 
behaves in patient cells. The challenge 
ahead is to close the circle and to 
apply what we have learned about 
the cell biology of this disease to 
the development of therapeutic 
approaches. The insights from HGPS 
have also opened an entirely new and 
fascinating vista on the aging process. 
Who would have guessed two years ago 
that architectural elements of the cell 
nucleus might contribute to aging? 
These advances have put us in the 
rare and desirable situation of possibly 
being able to making signiﬁ  cant steps 
towards understanding one of the most 
fascinating problems in biology—and 
at the same time do some good for 
patients and their families.  
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